KCT0009137招募中Unknown
A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease
AriBio0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 55(Year) 至 90(Year)（—）
- 性别
- All
入选标准
- •1. Male or female participants aged 55 to 90 years of age inclusive at the time of signing the informed consent form
- •2. Mild cognitive impairment or mild dementia consistent with AD defined by stages 3 to 4 according to the NIA AA (Jack et al., 2018) at Screening
排除标准
- •1. Participants who are female and are either pregnant, nursing, or of childbearing potential and not practicing effective contraception
- •2. Participants who have signs of significant delirium which, in the opinion of the investigator, would interfere with this study
研究者
相似试验
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of ELX/TEZ/IVA in Subjects Without an F508del MutatioMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2021-005320-38-PTVertex Pharmaceuticals Incorporated307
进行中（未招募）
1 期
An Investigation of the Safety and Efficacy of Odevixibat in Patients with Alagille syndromeAlagille SyndromeMedDRA version: 20.0Level: PTClassification code 10053870Term: Alagille syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004011-28-ITALBIREO AB52
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of ELX/TEZ/IVA in Subjects Without an F508del MutatioMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2021-005320-38-HUVertex Pharmaceuticals Incorporated270
已完成
3 期
A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR MutatioCystic FibrosisNL-OMON51518Vertex Pharmaceuticals15
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of ELX/TEZ/IVA in Subjects Without an F508del MutatioMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2021-005320-38-SEVertex Pharmaceuticals Incorporated270